Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03519997 · ClinicalTrials.gov registry record · Phase 2
A Study of Pembrolizumab and Bavituximab in Patients With Advanced Hepatocellular Carcinoma
A Phase 2 study of Hepatocellular Carcinoma, sponsored by David Hsieh.
- Active
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
- 2
- Study locations
NCT03519997 is a Phase 2 study of Hepatocellular Carcinoma that is active but no longer recruiting, run by David Hsieh. The registered enrollment target is 35 participants, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (86% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT03519997, a Phase 2 study of Hepatocellular Carcinoma, is active but no longer recruiting, sponsored by David Hsieh.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a non-randomized, open-label, multi-site phase II therapeutic trial of pembrolizumab and bavituximab in patients with locally advanced HCC. Locally advanced or metastatic HCC is defined as disease that is not amenable to surgical and/or locoregional therapies. Subjects must not have received prior systemic therapy for advanced HCC in keeping with the first-line setting of this study.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Bavituximab
Study Locations (2)
Texas
- Parkland Health & Hospital System - Dallas
- University of Texas Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2018-04-26 |
| Est. Completion | 2026-04-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03519997
The ClinicalTrials.gov registry entry for NCT03519997 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (86% lower). The listed sponsor is David Hsieh, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT03519997 reports 2 study locations spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT03519997 about?
NCT03519997 is a clinical study titled "A Study of Pembrolizumab and Bavituximab in Patients With Advanced Hepatocellular Carcinoma". This is a non-randomized, open-label, multi-site phase II therapeutic trial of pembrolizumab and bavituximab in patients with locally advanced HCC. Locally advanced or metastatic HCC is defined as disease that is not amenable to surgical and/or locoregional therapies. Subjects must not have received...
What is the current status of trial NCT03519997?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2018-04-26. Estimated completion is 2026-04-01.
What conditions does trial NCT03519997 study?
This clinical trial studies the following conditions: Hepatocellular Carcinoma.
What interventions are being tested in trial NCT03519997?
The interventions under investigation include: Pembrolizumab (DRUG), Bavituximab (DRUG).
Who is sponsoring clinical trial NCT03519997?
This trial is sponsored by David Hsieh, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03519997 being conducted?
This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Combination of TATE and PD-1 Inhibitor in Liver Cancer
RECRUITING · Phase 2
-
Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)
RECRUITING · Phase 2
-
Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma
RECRUITING · Phase 2
-
A Prospective Study of Memantine in Patients With Cirrhosis and Liver Cancer
RECRUITING · Phase 2
-
A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.